Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.

Clinical Pharmacology and Therapeutics
Chiaki TanakaH Schran

Abstract

This article describes studies that investigated the pharmacokinetics of nilotinib, a highly specific, oral, second-generation BCR-ABL tyrosine kinase inhibitor. After a once- or twice-daily regimen at doses ranging from 50 to 1,200 mg/day in 119 patients with chronic myeloid leukemia (CML), the area under the serum concentration-time curve (AUC) and peak serum concentration (C(max)) of nilotinib were found to be nearly dose proportional up to a dose of 400 mg once daily. Solubility-limited absorption at higher doses was observed, but this was partially overcome by dividing the daily dose into two. For instance, the administration of 400 mg nilotinib twice daily resulted in a 35% increase in AUC as compared to a once-daily dose of 800 mg. Exploratory pharmacodynamic assessment showed a general trend of greater reduction in white blood cell (WBC) levels with increase in nilotinib concentrations. This finding was consistent with the observation of an 82% reduction in WBC levels in patients after a regimen of 400 mg nilotinib twice daily for 15 days. The type and quantity of food intake variably affected nilotinib absorption. When administered after a high-fat meal, the AUC of nilotinib increased by 50% in CML patients (n = 10) an...Continue Reading

References

Nov 30, 2000·International Journal of Clinical Pharmacology and Therapeutics·W L ChiouH Y Jeong
Jun 14, 2001·Journal of Clinical Pharmacology·S K TeoS D Thomas
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bin PengRenaud Capdeville
Feb 16, 2005·Cancer Cell·Ellen WeisbergJames D Griffin
Oct 11, 2005·Critical Reviews in Oncology/hematology·Christoph Walz, Martin Sattler
May 25, 2006·British Journal of Cancer·E WeisbergJ D Griffin
Jun 16, 2006·The New England Journal of Medicine·Hagop KantarjianOliver G Ottmann
Dec 14, 2006·Acta Crystallographica. Section D, Biological Crystallography·Sandra W Cowan-JacobPaul W Manley
Sep 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Maitreyee HazarikaRichard Pazdur
Feb 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kevin M KochLionel D Lewis

❮ Previous
Next ❯

Citations

Apr 25, 2012·European Journal of Clinical Pharmacology·Akihito FujimiKenichi Sawada
Feb 25, 2011·Future Oncology·Paula Garland, Jane Apperley
Dec 3, 2010·Expert Opinion on Drug Safety·Theo Daniel Kim, Philipp le Coutre
Nov 16, 2010·Expert Opinion on Pharmacotherapy·Amber FullmerElias Jabbour
Apr 17, 2012·Expert Opinion on Investigational Drugs·An Tran, Hussein A Tawbi
Aug 13, 2010·Journal of Clinical Pharmacology·Chiaki TanakaHorst Schran
Jun 30, 2011·Journal of Clinical Pharmacology·Ophelia Q P YinHorst Schran
May 1, 2013·Drug Metabolism and Pharmacokinetics·Min-Jung KimJae-Gook Shin
Aug 16, 2015·International Journal of Pharmaceutics·Stefano ColomboMartin Malmsten
Feb 19, 2015·The Journal of Antibiotics·Aki IshiyamaKazuhiko Otoguro
Nov 20, 2009·Biochimica Et Biophysica Acta·Paul W ManleyDoriano Fabbro
Aug 23, 2016·Clinical Pharmacology in Drug Development·Peter N MorcosAlex Phipps
Oct 14, 2016·Leukemia & Lymphoma·Ayala Gover-ProaktorAvi Leader
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre LaneuvillePaul W Manley
May 10, 2017·Leukemia & Lymphoma·Naranie ShanmuganathanDavid Morrall Ross
Mar 23, 2017·Nature·Andrew A WylieWilliam R Sellers
Jun 24, 2017·The Journal of Pharmacy and Pharmacology·Christel C L M BoonsEleonora L Swart
Feb 3, 2015·Therapeutic Advances in Drug Safety·Gordon Mallarkey, Arduino A Mangoni
Feb 16, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ellin BermanRichard Burwick
Jan 19, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Guo YuHong-Hao Zhou
Sep 5, 2018·Journal of Clinical Pharmacology·Xianbin TianFlorence Hourcade-Potelleret

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.